Journal
ANNALS OF HEMATOLOGY
Volume 83, Issue 7, Pages 471-473Publisher
SPRINGER
DOI: 10.1007/s00277-003-0820-0
Keywords
beta-thalassemia major; heart failure; deferiprone; desferrioxamine; combined therapy
Categories
Ask authors/readers for more resources
Cardiac complications caused by iron deposition are major causes of death in patients with beta-thalassemia major. Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX). Furthermore, combined therapy with L1 and DFX produced an additive or synergistic iron chelating effect. We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy. Magnetic resonance images showed a marked recovery of signal intensity in the heart, indicating a significant reduction of iron load in the heart. No significant adverse effects were noted. Therefore, combined therapy with L1 and DFX should be considered in patients with beta-thalassemia major and cardiac complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available